Visualization of advanced human prostate cancer lesions in living mice by a targeted gene transfer vector and optical imaging

被引:132
作者
Adams, JY
Johnson, M
Sato, M
Berger, F
Gambhir, SS
Carey, M
Iruela-Arispe, ML
Wu, L [1 ]
机构
[1] Univ Calif Los Angeles, David Geffen Sch Med, Dept Urol, Los Angeles, CA 90095 USA
[2] Univ Calif Los Angeles, David Geffen Sch Med, Crump Inst Mol Imaging, Los Angeles, CA 90095 USA
[3] Univ Calif Los Angeles, David Geffen Sch Med, Dept Mol & Med Pharmacol, Los Angeles, CA 90095 USA
[4] Univ Calif Los Angeles, David Geffen Sch Med, Dept Biol Chem, Los Angeles, CA 90095 USA
[5] Univ Calif Los Angeles, Coll Letters & Sci, Dept Mol Cell & Dev Biol, Los Angeles, CA 90095 USA
关键词
D O I
10.1038/nm743
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Non-invasive imaging and transcriptional targeting can improve the safety of therapeutic approaches in cancer. Here we demonstrate the ability to identify metastases in a human-prostate cancer model, employing a prostate-specific adenovirus vector (AdPSE-BC-luc) and a charge-coupled device-imaging system. AdPSE-BC-luc, which expresses firefly luciferase from an enhanced prostate-specific antigen promoter, restricted expression in the liver but produced robust signals in prostate tumors. In fact, expression was higher in advanced, androgen-independent tumors than in androgen-dependent lesions. Repetitive imaging over a three-week period after AdPSE-BC-luc injection into tumor-bearing mice revealed that the virus could locate and illuminate metastases in the lung and spine. Systemic injection of low doses of AdPSE-BC-luc illuminated lung metastasis. These results demonstrate the potential use of a non-invasive imaging modality in therapeutic and diagnostic strategies to manage prostate cancer.
引用
收藏
页码:891 / 896
页数:6
相关论文
共 20 条
[1]   Economic evaluation of chemotherapy with mitoxantrone plus prednisone for symptomatic hormone-resistant prostate cancer: Based on a Canadian randomized trial with palliative end points [J].
Bloomfield, DJ ;
Krahn, MD ;
Neogi, T ;
Panzarella, T ;
Smith, TJ ;
Warde, P ;
Willan, AR ;
Ernst, S ;
Moore, MJ ;
Neville, A ;
Tannock, IF .
JOURNAL OF CLINICAL ONCOLOGY, 1998, 16 (06) :2272-2279
[2]  
Craft N, 1999, CANCER RES, V59, P5030
[3]   A mechanism for hormone-independent prostate cancer through modulation of androgen receptor signaling by the HER-2/neu tyrosine kinase [J].
Craft, N ;
Shostak, Y ;
Carey, M ;
Sawyers, CL .
NATURE MEDICINE, 1999, 5 (03) :280-285
[4]  
FREIDMANN T, 1999, DEV HUMAN GENE THERA
[5]  
Gregory CW, 2001, CANCER RES, V61, P4315
[6]   Gene therapy for prostate cancer: Current status and future prospects [J].
Harrington, KJ ;
Spitzweg, C ;
Bateman, AR ;
Morris, JC ;
Vile, RG .
JOURNAL OF UROLOGY, 2001, 166 (04) :1220-1233
[7]   Progression of metastatic human prostate cancer to androgen independence in immunodeficient SCID mice [J].
Klein, KA ;
Reiter, RE ;
Redula, J ;
Morad, H ;
Zhu, XL ;
Brothman, AR ;
Lamb, DJ ;
Marcelli, M ;
Belldegrun, A ;
Witte, ON ;
Sawyers, CL .
NATURE MEDICINE, 1997, 3 (04) :402-408
[8]   Comparative studies of the estrogen receptors β and α and the androgen receptor in normal human prostate glands, dysplasia, and in primary and metastatic carcinoma [J].
Leav, I ;
Lau, KM ;
Adams, JY ;
McNeal, JE ;
Taplin, ME ;
Wang, JF ;
Singh, H ;
Ho, SM .
AMERICAN JOURNAL OF PATHOLOGY, 2001, 159 (01) :79-92
[9]  
Linja MJ, 2001, CANCER RES, V61, P3550
[10]   The role of prostate specific antigen measurement in the detection and management of prostate cancer [J].
Nash, AF ;
Melezinek, I .
ENDOCRINE-RELATED CANCER, 2000, 7 (01) :37-51